Roche's new leukaemia drug superior to Rituxan in study

ZURICH (Reuters) - Roche's experimental leukaemia drug known as GA101 delayed disease progression in people with one of the most common forms of blood cancer longer than its top-seller Rituxan, the Swiss drugmaker said on Wednesday.

Source: http://feeds.reuters.com/~r/reuters/healthNews/~3/GwyxelGC7_I/story01.htm

phlebotomy certification el paso phlebotomy class california phlebotomy training in georgia